Drugs have so far failed to make an impact in established Alzheimer's disease, so research is moving towards efforts to prevent the disorder.
Vertex's cystic fibrosis drugs are among the most expensive ever evaluated by the US Institute for Clinical and Economic Research.
Could pricing pressure lead to the end of incremental innovation – and why does this matter?
Consolidation of hospital chains could give biopharma another powerful group of payers to contend with.
Amid a backlash over the high prices of advanced therapies, biotech companies are coming up with new payment models.
How the EMA's move out of London could impact European drug approvals.
Next-generation projects, including gene therapies, could soon be shaking up the haemophilia market.